Literature DB >> 22547737

Early tuberculosis treatment monitoring by Xpert(R) MTB/RIF.

Paolo Miotto, Sara Bigoni, Giovanni Battista Migliori, Alberto Matteelli, Daniela M Cirillo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22547737     DOI： 10.1183/09031936.00124711

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  28 in total

1.  Quantitative detection of cells expressing BlaC using droplet-based microfluidics for use in the diagnosis of tuberculosis.

Authors:  Fengjiao Lyu; Manqi Xu; Yunfeng Cheng; Jinghang Xie; Jianghong Rao; Sindy K Y Tang
Journal:  Biomicrofluidics       Date:  2015-08-20       Impact factor: 2.800

2.  Xpert MTB/RIF Results in Patients With Previous Tuberculosis: Can We Distinguish True From False Positive Results?

Authors:  Grant Theron; Rouxjeane Venter; Greg Calligaro; Liezel Smith; Jason Limberis; Richard Meldau; Duncan Chanda; Aliasgar Esmail; Jonny Peter; Keertan Dheda
Journal:  Clin Infect Dis       Date:  2016-02-16       Impact factor: 9.079

Review 3.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

Review 4.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

Review 5.  Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.

Authors:  Stephen D Lawn; Peter Mwaba; Matthew Bates; Amy Piatek; Heather Alexander; Ben J Marais; Luis E Cuevas; Timothy D McHugh; Lynn Zijenah; Nathan Kapata; Ibrahim Abubakar; Ruth McNerney; Michael Hoelscher; Ziad A Memish; Giovanni Battista Migliori; Peter Kim; Markus Maeurer; Marco Schito; Alimuddin Zumla
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

Review 6.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Hojoon Sohn; Ian Schiller; Lorie A Kloda; Catharina C Boehme; Madhukar Pai; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

7.  Molecular logic gates for DNA analysis: detection of rifampin resistance in M. tuberculosis DNA.

Authors:  Evan M Cornett; Eleanor A Campbell; George Gulenay; Evan Peterson; Neha Bhaskar; Dmitry M Kolpashchikov
Journal:  Angew Chem Int Ed Engl       Date:  2012-08-09       Impact factor: 15.336

8.  Detection and Quantification of Viable and Nonviable Trypanosoma cruzi Parasites by a Propidium Monoazide Real-Time Polymerase Chain Reaction Assay.

Authors:  Beatriz Cancino-Faure; Roser Fisa; M Magdalena Alcover; Teresa Jimenez-Marco; Cristina Riera
Journal:  Am J Trop Med Hyg       Date:  2016-05-02       Impact factor: 2.345

9.  Diagnosis of Concurrent Pulmonary Tuberculosis and Tuberculous Otitis Media Confirmed by Xpert MTB/RIF in the United States.

Authors:  Kathleen M Tompkins; Melissa A Reimers; Becky L White; Michael E Herce
Journal:  Infect Dis Clin Pract (Baltim Md)       Date:  2016-05

10.  Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity.

Authors:  Xavier A Kayigire; Sven O Friedrich; Amour Venter; Rodney Dawson; Stephen H Gillespie; Martin J Boeree; Norbert Heinrich; Michael Hoelscher; Andreas H Diacon
Journal:  J Clin Microbiol       Date:  2013-04-17       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.